5つのAIイラストレーションテクニックで、インパクトのある学会発表を

Conference presentation opening slide for cancer immunotherapy breakthrough, 16:9
widescreen format, designed for large auditorium projection with dramatic visual
impact and space for title text.

Center stage: Highly detailed tumor microenvironment showing solid tumor mass in
muted gray-purple tones, surrounded by activated CAR-T cells (shown as dynamic blue
spherical immune cells with surface receptors) labeled "CAR-T Cells" actively
engaging tumor cells. Bright green fluorescent markers indicate "Cytotoxic Activity"
at interaction points.

Foreground detail: Magnified CAR-T cell showing chimeric antigen receptor proteins
binding to tumor antigen, molecular interaction shown with glowing connection points,
creating focal depth.

Background elements: Tumor vasculature network in dark red, immune checkpoint
molecules visible but faded indicating blockade, stromal support cells in
supporting role.

Lighting: Dramatic spotlight from upper left creating depth and focus, bioluminescent
glow from active T-cells providing dynamic energy, deep gradient background
transitioning navy blue to deep purple.

Top third留白 for slide title placement with white/light text space, bottom right
corner space reserved for institution logo. Ultra high contrast for projector
visibility, modern scientific photography style similar to Nature cover art,
cinematic lighting, professional conference aesthetic.

Data storytelling infographic for global temperature rise conference presentation,
16:9 landscape format, designed for climate science talk with compelling visual
narrative structure.

Central metaphor: Large clinical thermometer positioned vertically center-right,
mercury column showing dramatic rise from bottom "1880 baseline: 13.7°C" to top
"2023: 15.1°C" with gradient color shift from cool blue at bottom through
yellow-orange to alarming red at top. Temperature scale marked with decade intervals.

Background context: Stylized Earth in left half showing Arctic region with visible
ice sheet reduction via semi-transparent overlay comparing "1979" (extensive white
ice coverage) vs "2023" (significantly reduced ice, more blue ocean exposed),
labeled "Arctic Sea Ice Loss: -13% per decade".

Supporting data elements: Small line graph embedded lower left showing "CO₂
Concentration: 280 ppm → 420 ppm" with upward trajectory, small bar chart lower
right showing "Sea Level Rise: +21 cm since 1880" with coastal city silhouette
for context.

Timeline ribbon across bottom: Horizontal timeline 1880-2023 with milestone markers:
"1950: Acceleration Begins", "1988: IPCC Established", "2015: Paris Agreement",
"2023: Warmest Year", each with small iconic visual.

Color psychology: Cool blues (past/baseline) transitioning to warm oranges and reds
(present/warning), creating emotional narrative arc. Clean sans-serif labels in
white and dark gray for high contrast, modern infographic style similar to IPCC
reports, data source notation "Data: NASA GISS" in small text, professional
conference aesthetic for large projection.

Clinical trial methodology infographic for pharmaceutical conference presentation,
16:9 horizontal format, clear workflow visualization for medical professional
audience showing Phase I-IV progression.

Left-to-right progression with 4 major phases connected by bold blue arrows:

Phase I (leftmost): "Phase I: Safety Testing" - Small group of diverse human
silhouettes labeled "n=80 healthy volunteers", test tube icons labeled "Dose
Escalation", stopwatch showing "6-12 months", safety shield icon labeled "Toxicity
Assessment", green checkmark "Safe Dosage Identified".

Phase II (center-left): "Phase II: Efficacy Testing" - Larger patient group icon
labeled "n=240 patients with Disease X", magnifying glass over cells labeled
"Biomarker Analysis", split arrow showing "Treatment Arm (n=160)" vs "Placebo Arm
(n=80)", bar chart showing "Primary Endpoint: 35% Response Rate", timeline "18-24
months", yellow checkmark "Promising Efficacy".

Phase III (center-right): "Phase III: Confirmatory Study" - Large multi-site icon
labeled "n=2400 across 25 sites", world map background indicating "International
Multi-Center Trial", randomization symbol labeled "2:1 Randomization", survival
curve graph labeled "Overall Survival: HR=0.72, p<0.001", clipboard icon "Regulatory
Package", timeline "3-4 years", orange checkmark "Primary Endpoint Met".

Phase IV (rightmost): "Phase IV: Post-Market Surveillance" - Population-scale icon
labeled "Real-World Evidence", database icon labeled "Adverse Event Monitoring",
clipboard with charts "Long-Term Safety", continuous timeline arrow labeled "Ongoing
Monitoring", blue checkmark "Market Approval".

Vertical annotations: Risk indicators - Phase I "High Risk: 10% failure", Phase III
"Moderate Risk: 50% failure". Cost indicators - escalating dollar signs $ to $$$$.

Timeline bar at bottom showing "Total Development: 5-8 years", regulatory milestone
flags: "IND Application", "FDA Fast Track", "NDA Approval".

Modern medical infographic style with teal-blue-purple color scheme, consistent
icon design, clean white background, high contrast labels in Arial font, suitable
for large conference projection, professional pharmaceutical aesthetic.

Conference presentation conclusion slide with three-pillar visual summary for
research breakthrough, 16:9 landscape format, memorable and scannable design for
final slide impact.

Architectural metaphor: Three elegant classical columns supporting platform above,
each representing major research contribution, minimalist modern interpretation
with clean lines and gradients.

Left column (blue gradient): "Pillar 1: Novel Mechanism Discovery" - Column
decorated with molecular structure motifs, DNA helix wrapping base, microscope icon
at capital, key points floating beside: "• Identified CRISPR-Cas13 RNA targeting",
"• 95% specificity improvement", "• Published in Cell". Height extends to platform.

Center column (purple gradient): "Pillar 2: Clinical Translation" - Column adorned
with medical cross symbols, patient silhouettes, heartbeat line decoration, key
points: "• Phase IIb: 67% response rate", "• Safe in 156 patients", "• FDA
Breakthrough Designation". Slightly taller emphasizing primary contribution.

Right column (teal gradient): "Pillar 3: Scalable Manufacturing" - Column featuring
bioreactor icons, production facility symbols, globe network pattern, key points:
"• Cost reduced 10-fold", "• Production time: 7 days", "• 5 global facilities ready".
Matches left height.

Top platform (golden gradient): Unified discovery name "PROJECT GENESIS:
Next-Generation Gene Therapy" resting on three pillars, showing structural integrity
and interdependence.

Foundation base: Institutional logos and funding acknowledgments in marble-like base
"Stanford Medicine | NIH R01 | 2020-2025", showing solid support.

Background: Soft gradient white (top) to light blue-purple (bottom), professional
depth with subtle radial glow behind center. Small achievement badges floating:
"5 Patents Filed", "2 Spin-out Companies", "12 Publications".

Clean typography: Column titles bold sans-serif (28pt), bullet points lighter (18pt),
high-contrast dark text on light columns, designed for back-row readability, modern
conference aesthetic, inspirational yet professional similar to TED finale slides.

Conference Q&A backup slide showing alternative hypothesis comparison, 4:3 aspect
ratio for projection system compatibility, self-contained scientific explanation
for mechanism question.

Split-screen layout with clear vertical divider:

Left panel (60% width): "Our Proposed Mechanism: Direct Pathway" - Simplified
cellular signaling cascade numbered 1-4. Step 1: "Receptor X activation" with
ligand binding to GPCR, labeled "Agonist binding (10 nM)". Step 2: "G-protein
dissociation" with α/β/γ subunits separating, labeled "Gαq pathway". Step 3: "PLC
activation → IP3 + DAG" with enzyme activity icon, labeled "Phospholipase C".
Step 4: "Calcium release from ER" with Ca²⁺ flooding cytoplasm, labeled "Immediate
response (<30 sec)". Timeline: "Fast Response: 30 seconds". Data reference:
"Figure 3C, p=0.002".

Right panel (40% width): "Alternative Hypothesis: Indirect Pathway" - Traditional
textbook pathway. Step 1: Same receptor activation. Step 2: "β-arrestin recruitment"
instead of G-protein, labeled "Scaffold protein". Step 3: "MAPK cascade" with
Ras→Raf→MEK→ERK sequence, labeled "Kinase phosphorylation". Step 4: "Nuclear gene
transcription" with delayed effects, labeled "Delayed response (>30 min)". Timeline:
"Slow Response: 30+ min". Reference: "Smith et al. 2018".

Center divider: Large "VS." at top, bidirectional arrow at bottom "Key Difference:
Timing & Mechanism". Callout boxes: "We bypass slow MAPK pathway" and "Direct
calcium signaling explains rapid phenotype".

Top banner: "Q: Why not β-arrestin signaling?" in clear question format.

Bottom evidence box: "Supporting Evidence:" with mini data thumbnails - Western blot
"No β-arrestin recruitment", calcium trace "Rapid Ca²⁺ spike", pharmacology table
"Pathway inhibitor results".

Color coding: Our pathway confident blue-green gradient, alternative neutral
gray-purple, red X on disproven steps, green checkmarks on validated steps.
Professional molecular biology style, clean white background, Arial labels with
size hierarchy (titles 24pt, labels 16pt, annotations 12pt), high contrast for
quick Q&A comprehension, matches main presentation style, authoritative tone.